Canada — Canada s Drug Agency
Tracked across 4 events · 25 articles · First seen Jul 06, 2026 · Last active Sep 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Issued updated recommendation to fund lecanemab for early-stage Alzheimer's, reversing earlier decision.
Jul 16, 2026 · 7 articles
Regulatory
Impact: The agency issued the final positive recommendation, a key regulatory step that facilitates public reimbursement of Leqembi in Canada.
Sep 01, 2026 · 6 articles
Business
Impact: CDA-AMC issued a positive reimbursement recommendation for ALYFTREK in December 2025, which preceded the LOI.
Jul 06, 2026 · 6 articles
Business
Boehringer Ingelheim announced the launch of PED Essentials, a free online e-learning hub designed to help patient organizations generate, analyze and share high-quality patient experience data (PED). The platform was co-created with patients and subject…
Impact: Canada — Canada s Drug Agency is cited alongside NICE as increasingly using patient evidence in HTA and reimbursement decisions, supporting the rationale for the PED Essentials hub.
Sep 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Canada — Canada s Drug Agency live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard